• Alias: SB1518
    • Inhibitor of JAK, mainly JAK2, and FLT3 developed for the treatment of myelofibrosis
    • Currently in phase 3 clinical trials for myelofibrosis
    • Recommended dose: 200 to 400 mg PO daily
    • Half-life: 2 to 3 days
    • Common side effects: Diarrhea, nausea, thrombocytopenia
    (Verstovsek et al., 2009)
    Other topics in Targeted and Immunotherapy Agents